Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Zhejiang Chemsyn Pharm CoBJSE:920656 36 EV-to-FCF is 29.26 as of Jul. 29, 2026, which is 43% below its 10-year median of 51.29. GuruFocus rates BJSE:920656 with a GF Score™ of 36/100. The stock has 4 warning signs investors should review. Among 17 Healthcare Plans companies, Zhejiang Chemsyn Pharm Co ranks worse than 76.47% on this metric.
EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Zhejiang Chemsyn Pharm Co's Enterprise Value is ¥906.9 Mil.
Zhejiang Chemsyn Pharm Co's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 was ¥31.0 Mil. Therefore, Zhejiang Chemsyn Pharm Co's EV-to-FCF for today is 29.26.
The historical rank and industry rank for Zhejiang Chemsyn Pharm Co's EV-to-FCF or its related term are showing as below:
BJSE:920656'
s EV-to-FCF Range Over the Past 10 Years
Min: -621.74 Med: 51.29 Max: 1380.44
Current: 28
During the past 12 years, the highest EV-to-FCF of Zhejiang Chemsyn Pharm Co was 1380.44. The lowest was -621.74. And the median was 51.29.
BJSE:920656's EV-to-FCF is ranked worse than 76.47% of 17
companies
in the Healthcare Plans industry
Industry Median: 18.26
vs BJSE:920656: 28.00
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Zhejiang Chemsyn Pharm Co (BJSE:920656) EV-to-FCF Explanation
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Zhejiang Chemsyn Pharm Co's PE Ratio (TTM) for today is calculated as:
Zhejiang Chemsyn Pharm Co's share price for today is ¥13.43.
Zhejiang Chemsyn Pharm Co's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥0.760.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Zhejiang Chemsyn Pharm Co EV-to-FCF Related Terms
Zhejiang Chemsyn Pharm Co EV-to-FCF Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BJSE:920656 vs UNH, CVS, ELV: EV-to-FCF Comparison
For the Healthcare Plans subindustry, Zhejiang Chemsyn Pharm Co's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Zhejiang Chemsyn Pharm Co EV-to-FCF vs Healthcare Plans Industry
For the Healthcare Plans industry and Healthcare sector, Zhejiang Chemsyn Pharm Co's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Zhejiang Chemsyn Pharm Co's EV-to-FCF falls into.
Zhejiang Chemsyn Pharm Co's current Enterprise Value is ¥906.9 Mil.
Zhejiang Chemsyn Pharm Co's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥31.0 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Zhejiang Chemsyn Pharm Co (BJSE:920656) has a EV-to-FCF of 29.26 as of Jul. 29, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Zhejiang Chemsyn Pharm Co and its competitors. This is 43% below median its historical median of 51.29. According to the industry distribution chart, Zhejiang Chemsyn Pharm Co ranks #13 out of 17 companies in the Healthcare Plans industry, placing it in the top 76.5%.
Is Zhejiang Chemsyn Pharm Co's EV-to-FCF too high?
Zhejiang Chemsyn Pharm Co's current EV-to-FCF of 29.26 is 43% below median its 10-year median of 51.29. The Healthcare Plans industry median EV-to-FCF is 18.26. Zhejiang Chemsyn Pharm Co's value of 29.26 is 60.2% above this industry median. Based on the distribution chart, Zhejiang Chemsyn Pharm Co ranks #13 out of 17 companies in the Healthcare Plans industry, which is in the bottom quartile relative to peers. Overall, Zhejiang Chemsyn Pharm Co has a GF Score™ of 36/100, reflecting its overall financial health beyond just this single metric.
How does Zhejiang Chemsyn Pharm Co's EV-to-FCF compare to UNH and CVS?
According to the Healthcare Plans industry distribution chart, Zhejiang Chemsyn Pharm Co ranks #13 out of 17 companies for EV-to-FCF. This places Zhejiang Chemsyn Pharm Co in the lower half of its industry. The industry median EV-to-FCF is 18.26. Zhejiang Chemsyn Pharm Co's value of 29.26 is 60.2% above this benchmark. While the company's 10-year median is 51.29 vs. the industry median of 18.26, Zhejiang Chemsyn Pharm Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Healthcare Plans company?
The median EV-to-FCF among Healthcare Plans companies is 18.26, based on 17 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Zhejiang Chemsyn Pharm Co's current EV-to-FCF of 29.26 is 60.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Zhejiang Chemsyn Pharm Co and its competitors. For the Healthcare Plans industry, the median EV-to-FCF is 18.26 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Zhejiang Chemsyn Pharm Co's current EV-to-FCF is 29.26, which is 43% below median its own 10-year median of 51.29. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Zhejiang Chemsyn Pharm Co stock overvalued right now?
Zhejiang Chemsyn Pharm Co (BJSE:920656) has a current EV-to-FCF of 29.26. The current EV-to-FCF is 29.26, which is 43% below median its 10-year median of 51.29 and 60.2% above the Healthcare Plans industry median of 18.26. Zhejiang Chemsyn Pharm Co's overall GF Score™ is 36/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Zhejiang Chemsyn Pharm Co (BJSE:920656), the current EV-to-FCF is 29.26 as of Jul. 29, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Zhejiang Chemsyn Pharm Co Ltd is engaged in Research, development, production and sales of veterinary drug raw materials, pharmaceutical raw materials and intermediates.
36GF Score
Get the complete analysis for BJSE:920656
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BJSE:920656 has been successfully added to your 
